Today were reported SPDR S&P Biotech (ETF) (NYSEARCA:XBI)‘s daily net flows. The ETF registered $-84.51M asset outflows for -2.37% decrease, reaching $3481.69M after yestarday’s trading session. The chart of SPDR S&P Biotech (ETF) shows negative short-term setup. In the net flows calculation is not included the performance of the etf but only share redemptions (outflows) and share purchases (inflows). Net outflows leads to less cash for managers to invest, which theoretically decreases demand for the etf’s holdings. The ETF increased 1.48% or $0.97 on November 17, hitting $66.48. It is down 15.88% since April 18, 2016 and is uptrending. It has outperformed by 11.45% the S&P500.
The ETF’s YTD performance is -19.81%, the 1 year is -15.34% and the 3 year is 13.06%.
The ETF’s average P/E ratio is 19.64, the price to book is 2.76, the price to sales is 7.08 and the price to cashflow is 10.94. SPDR S&P Biotech (ETF) is in the ETF category: , is part of the fund family and currently has $ net assets. It was started on 1/1/0001. The fund’s top holdings are: Sarepta Therapeutics Inc. for 3.86% of assets, TESARO Inc. for 3.53%, Incyte Corporation for 2.94%, Alexion Pharmaceuticals Inc. for 2.80%, United Therapeutics Corporation for 2.68%, Celgene Corporation for 2.62%, Gilead Sciences Inc. for 2.53%, Biogen Inc. for 2.53%, Regeneron Pharmaceuticals Inc. for 2.40%, Ionis Pharmaceuticals Inc. for 2.40%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as 0% yield.
More notable recent SPDR S&P Biotech (ETF) (NYSEARCA:XBI) news were published by: Investorplace.com which released: “Try the SPDR S&P Biotech (ETF) (XBI) if You’re Bullish on the Biotech Pause” on November 16, 2016, also Investorplace.com with their article: “Buy the SPDR S&P Biotech (ETF) (XBI) TODAY â€“ Here’s Why” published on November 09, 2016, Bloomberg.com published: “Options Insight: How to Trade the SPDR S&P Biotech ETF” on October 06, 2016. More interesting news about SPDR S&P Biotech (ETF) (NYSEARCA:XBI) were released by: Benzinga.com and their article: “Dan Nathan’s SPDR S&P Biotech ETF Trade” published on October 24, 2016 as well as Investorplace.com‘s news article titled: “SPDR S&P Biotech (ETF) (XBI): Embrace the Biotech Bulls’ Return” with publication date: August 11, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.